Prostate Cancer | Tanya B Dorff, MD

Want to Beat Prostate Cancer? Watch This NowПодробнее

#UromigosLive24 Radioligands Part 1: VISION and PSMAFore DiscussionПодробнее

#UromigosLive24 T Cell Directed Therapy Panel Part 2: Existing Data for T Cell Engagers in CRPCПодробнее

#UromigosLive24 T Cell Directed Therapy Panel Part 1: T Cell Engagers and Cytokine Release SyndromeПодробнее

Uromigos Live 2024 Radioligands Part 1: SPLASH Results from ESMO 2024Подробнее

Discussing Novel Radiopharmaceuticals in Development for CRPCПодробнее

Barriers to the Use of Radioligands and Navigating Patients Through Multi-Disciplinary CareПодробнее

Discussing New Game-Changing Studies in Prostate CancerПодробнее

PSMA/PET Scans and ADT in Patients With CRPCПодробнее

Decision-Making When Considering ADT and Doublet or Triplet Therapy for CRPCПодробнее

Uromigos Live 2024 Highlights: The Evolving Role of ADT in Prostate CancerПодробнее

T Cell Directed Therapy in Prostate Cancer: Uromigos Live 2024Подробнее

Episode 3 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Met...Подробнее

Episode 1 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Met...Подробнее

Episode 2 - Talking Prostate Cancer: Homologous Recombination Repair Gene Mutation Testing in Met...Подробнее

Clinical Trials with Dr DorffПодробнее

Uromigos Live 2023: Current and Future Status of Radioligand Therapy in Prostate CancerПодробнее

Uromigos Live 2023: Where Do We Stand With PARP Inhibitors in Prostate Cancer?Подробнее

Looking Ahead: What Does the Future Hold for Radioligand Therapy in Prostate Cancer?Подробнее